rethinkTHC Search
Menu
Study breakdown

Why Cannabis Is an "Atypical" Drug of Abuse: Unusual Patterns in Animal Addiction Models

ReviewModerate evidence
The takeaway

Unlike opioids, cocaine, or alcohol, cannabinoids only produce rewarding effects in animals under very specific experimental conditions, earning them the label of "atypical" or "anomalous" drugs of abuse.

Read this if you want to understand why scientists consider cannabis a different kind of addictive substance compared to opioids, cocaine, or alcohol.

Cannabinoids produce reward in animals only under "particular experimental conditions"

What the researchers found

This comprehensive review examined preclinical (animal) evidence for the reinforcing and dependence-producing properties of cannabinoids.

The central finding was that cannabinoids behave differently from other drugs of abuse in standard laboratory paradigms. While opioids, stimulants, alcohol, and nicotine reliably produce self-administration and conditioned place preference in animals, cannabinoids do so only under narrow, specific experimental conditions.

This inconsistency in animal models contrasted with the clear subjective rewarding effects cannabis produces in humans, leading to cannabinoids being classified as "atypical" drugs of abuse.

The review also covered endocannabinoid system modulators (FAAH inhibitors, endocannabinoid transport inhibitors) and their reinforcing properties, finding these generally lacked abuse liability compared to direct CB1 agonists like THC.

Why it matters

The gap between animal and human evidence for cannabis reward has been a longstanding puzzle in addiction research. Understanding why cannabinoids are "atypical" helps explain their unique addiction profile: relatively low but non-zero addiction potential compared to many other drugs.

The numbers in context

Cannabis is the most widely used illicit drug globally. Cannabinoids produce reinforcement in animals only under "particular experimental conditions." Endocannabinoid modulators generally showed lower abuse liability than direct CB1 agonists.

How the study worked

Comprehensive narrative review of preclinical behavioral pharmacology studies examining cannabinoid reward, reinforcement, and dependence, including self-administration, conditioned place preference, intracranial self-stimulation, and physical dependence paradigms.

What this study cannot tell us

Narrative review format. Animal models may miss important aspects of human addiction. The conditions under which cannabinoids are reinforcing in animals may reveal something about cannabinoid pharmacology or may reflect limitations of the animal models themselves.

How to read the evidence

This is a comprehensive review of preclinical evidence, providing moderate evidence about cannabinoid reward pharmacology and its unique characteristics compared to other drugs.

When this study was published

Published in 2008. Research has since identified specific conditions (low doses, certain genetic strains, prior drug exposure) under which cannabinoid self-administration is more reliably produced in animals.

The bigger picture

This review helped frame cannabis's position in the spectrum of addictive substances. Its "atypical" profile in animal models is consistent with epidemiological data showing that while cannabis dependence occurs, its rate and severity are generally lower than for substances like alcohol, opioids, or nicotine.

Questions still open

  • What makes cannabinoids reinforcing only under specific conditions in animals? Do endocannabinoid system modulators truly have lower abuse potential, or are the animal models inadequate for detecting it?

Common questions

If animals don't self-administer cannabis easily, does that mean it's not addictive?
Not exactly. Cannabis clearly has rewarding effects in humans and some people develop dependence. The animal findings suggest cannabis has a different pharmacological profile than other drugs, explaining its lower but still real addiction potential.
Why are cannabinoids "atypical"?
Most drugs of abuse reliably produce self-administration in laboratory animals under standard conditions. Cannabinoids require specific experimental manipulations (particular doses, schedules, or animal strains) to show the same effects, suggesting a unique mechanism of reward.

Read the original research

Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties.

Current drug abuse reviews, 1(3), 350-74

Citation

Panagis, George; Vlachou, Styliani; Nomikos, George G. (2008). Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties.. Current drug abuse reviews, 1(3), 350-74.

Explore the wider topic